Adherence to Anti‐Staphylococcal Prophylaxis in the First Two Years of Life and Microbiological Outcomes in the First Six Years of Life in Children With Cystic Fibrosis

Documenti analoghi

• Cystic Fibrosis Year in Review 2024
  di: Adrienne P. Savant
  Pubblicazione: (2025)
• Impact of Elexacaftor‐Tezacaftor‐Ivacaftor on Quality of Life in Children With Cystic Fibrosis
  di: Sara Kümmerli, et al.
  Pubblicazione: (2026)
• Global Research Status and Trends in Quality of Life in Children With Cystic Fibrosis From 1985 to 2025: A 40‐Year Bibliometric Analysis
  di: Kızbes Meral Kılıç, et al.
  Pubblicazione: (2026)
• Outpatient Respiratory Outcomes in Extremely Preterm Children During the First 3 Years of Life
  di: Cynara Leon, et al.
  Pubblicazione: (2025)
• Investigating the Potential Hearing Impairment and Ototoxicity in Children up to Six Years With Cystic Fibrosis After Aminoglycoside Exposure (PIANO‐CF Extension)
  di: Elena K. Schneider‐Futschik, et al.
  Pubblicazione: (2025)